Developmental changes of aldehyde oxidase activity and protein expression in human liver cytosol

Drug Metabolism and Pharmacokinetics

Volumn 27, Issue 5, 2012, Pages 543-547

  Tayama, Yoshitaka ^a   Sugihara, Kazumi ^a,b   Sanoh, Seigo ^b   Miyake, Katsushi ^a   Kitamura, Shigeyuki ^b,c   Ohta, Shigeru ^b  

^a HIROSHIMA INTERNATIONAL UNIVERSITY   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

^c NIHON PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Aldehyde oxidase; Children; Developmental change; Human; Liver

Indexed keywords

1 METHYL 6 OXONICOTINAMIDE; 1 METHYLNICOTINAMIDE; ALDEHYDE OXIDASE; AMIDE; N 1 METHYL 4 PYRIDONE 3 CARBOXAMIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE DISTRIBUTION; ARTICLE; CHILD; DEVELOPMENTAL BIOLOGY; DEVELOPMENTAL CHANGE; DEVELOPMENTAL STAGE; DRUG OXIDATION; ENZYME ACTIVITY; ENZYME REGULATION; FEMALE; HUMAN; HUMAN TISSUE; INFANT; LIVER CYTOSOL; MALE; PRESCHOOL CHILD; PROTEIN EXPRESSION; SCHOOL CHILD;

EID: 84869112935     PISSN: 13474367     EISSN: 18800920     Source Type: Journal    
DOI: 10.2133/dmpk.DMPK-11-NT-124     Document Type: Article

References (34)

1. Beedham, C.: Molybdenum hydroxylases as drug metabolizing enzyme. Drug Metab. Rev., 16: 119-156 (1985).
2. Berger, R., Mezey, E., Clancy, K. P., Harta, G., Wright, R. M., Repine, J. E., Brown, R. H., Brownstein, M. and Patterson, D.: Analysis of aldehyde oxidase and xanthine dehydrogenase/oxidase as possible candidate genes for autosomal recessive familial amyotrophic lateral sclerosis. Somat. Cell Mol. Genet., 21: 121-131 (1995).
3. Moriwaki, Y., Yamamoto, T. and Higashino, K.: Distribution and pathophysiologic role of molybdenum-containing enzymes. Histol. Histopathol., 12: 513-524 (1997).
4. Wright, R. M., Vaitaitis, G. M., Weigel, L. K., Repine, T. B., McManaman, J. L. and Repine, J. E.: Identification of the candidate ALS2 gene at chromosome 2q33 as a human aldehyde oxidase gene. Redox Rep., 1: 313-321 (1995).
5. Krenitsky, T. A., Tuttle, J. V., Cattau, E. L. and Wang, P.: A comparison of the distribution and electron acceptor specificities of xanthine oxidase and aldehyde oxidase. Comp. Biochem. Physiol. B, 49: 687-703 (1974).
6. Beedham, C., al-Tayib, Y. and Smith, J. A.: Role of guinea pig and rabbit hepatic aldehyde oxidase in oxidative in vitro metabolism of cinchona antimalarials. Drug Metab. Dispos., 20: 889-895 (1992).
7. Moriyasu, A., Sugihara, K., Nakatani, K., Ohta, S. and Kitamura, S.: In vivo-in vitro relationship of methotrexate 7-hydroxylation by aldehyde oxidase in four different strain rats. Drug Metab. Pharmacokinet., 21: 485-491 (2006).
8. Jordan, C. G., Rashidi, M. R., Laljee, H., Clarke, S. E., Brown, J. E. and Beedham, C.: Aldehyde oxidase-catalyzed oxidation of methotrexate in the liver of guinea-pig, rabbit and man. J. Pharm. Pharmacol., 51: 411-418 (1999).
9. Clarke, S. E., Harrell, A. W. and Chenery, R. J.: Role of aldehyde oxidase in the in vitro conversion of famciclovir to penciclovir in human liver. Drug Metab. Dispos., 23: 251-254 (1995).
10. Rashidi, M. R., Smith, J. A., Clarke, S. E. and Beedham, C.: In vitro oxidation of famciclovir and 6-deoxypenciclovir by aldehyde oxidase from human, guinea pig, rabbit, and rat liver. Drug Metab. Dispos., 25: 805-813 (1997).
11. Inaba, T., Fayz, S. and Stewart, D. J.: Aldehyde oxidase inhibitors for treatment of AIDS. United States Patent, 6: 400-434 (2000).
12. Sugihara, K., Kitamura, S. and Tatsumi, K.: Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide. Drug Metab. Dispos., 24: 199-202 (1996).
13. Lupp, A., Danz, M. and Muller, D.: Histomorphological changes and cytochrome P450 isoforms expression and activities in precision-cut liver slices from neonatal rats. Toxicology, 206: 427-438 (2005).
14. Yoon, M., Madden, M. C. and Barton, H. A.: Developmental expression of aldehyde dehydrogenase in rat: a comparison of liver and lung development. Toxicol. Sci., 89: 386-398 (2006).
15. Johnson, T. N.: The development of drug metabolising enzymes and their influence on the susceptibility to adverse drug reactions in children. Toxicology, 192: 37-48 (2003).
16. Leeder, J. S., Gaedigk, R., Marcucci, K. A., Gaedigk, A., Vyhlidal, C. A., Schindel, B. P. and Pearce, R. E.: Variability of CYP3A7 expression in human fetal liver. J. Pharmacol. Exp. Ther., 314: 626-635 (2005).
17. Cotreau, M. M., von Moltke, L. L. and Greenblatt, D. J.: The influence of age and sex on the clearance of cytochrome P450 3A Substrates. Clin. Pharmacokinet., 44: 33-60 (2005).
18. Lacroix, D., Sonnier, M., Moncion, A., Cheron, G. and Cresteil, T.: Expression of CYP3A in the human liver-evidence that the shift between CYP3A7 and CYP3A4 occurs immediately after birth. Eur. J. Biochem., 247: 625-634 (1997).
19. Koukouritaki, S. B., Simpson, P., Yeung, C. K., Rettie, A. E. and Hines, R. N.: Human hepatic flavin-containing monooxygenases 1 (FMO1) and 3 (FMO3) developmental expression. Pediatr. Res., 51: 236-243 (2002).
20. McCarver, D. G. and Hines, R. N.: The ontogeny of human drugmetabolizing enzymes: phase II conjugation enzymes and regulatory mechanisms. J. Pharmacol. Exp. Ther., 300: 361-366 (2002).
21. Kawade, N. and Onishi, S.: The prenatal and postnatal development of UDP-glucuronyltransferase activity towards bilirubin and the effect of premature birth on this activity in human liver. Biochem. J., 196: 257-260 (1981).
22. Tayama, Y., Moriyasu, A., Sugihara, K., Ohta, S. and Kitamura, S.: Developmental changes of aldehyde oxidase in postnatal rat liver. Drug Metab. Pharmacokinet., 22: 119-124 (2007).
23. Pullman, M. E. and Colowick, S. P.: Preparation of 2-and 6-pyridones of N1-methylnicotinamide. J. Biol. Chem., 206: 121-127 (1954).
24. Shibata, K., Kawada, T. and Iwai, K.: Stimultaneous micro-determination of nicotinamide and its major metabolites, N1-methyl-2-pyridone-5-carboxamide and N1-methyl-4-pyridone-3-carboxamide, by high-performance liquid chromatography. J. Chromatogr., A, 424: 23-28 (1988).
25. Lowry, O. H., Rosebrough, N. J., Farr, A. L. and Randall, R. J.: Protein measurement with the Folin phenol reagent. J. Biol. Chem., 193: 265-275 (1951).
26. Ohkubo, M., Sakiyama, S. and Fujimura, S.: Purification and characterization of N1-methylnicotinamide oxidase I and II separated from rat liver. Arch. Biochem. Biophys., 221: 534-542 (1983).
27. Tayama, Y., Miyake, K., Sugihara, K., Kitamura, S., Kobayashi, M., Morita, S., Ohta, S. and Kihira, K.: Developmental changes of aldehyde oxidase activity in young Japanese children. Clin. Pharmacol. Ther., 81: 567-572 (2007).
28. Kitamura, S., Sugihara, K. and Ohta, S.: Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab. Pharmacokinet., 21: 83-98 (2006).
29. Sugihara, K., Tayama, Y., Shimomiya, K., Yoshimoto, D., Ohta, S. and Kitamura, S.: Estimation of aldehyde oxidase activity in vivo from conversion ratio of N1-methylnicotinamide to pyridones, and intraspecies variation of the enzyme activity in rats. Drug Metab. Dispos., 34: 208-212 (2006).
30. Ueda, O., Sugihara, K., Ohta, S. and Kitamura, S.: Involvement of molybdenum hydroxylases in reductive metabolism of nitro polycyclic aromatic hydrocarbons in mammalian skin. Drug Metab. Dispos., 33: 1312-1318 (2005).
31. Tayama, Y., Sugihara, K., Sanoh, S., Miyake, K., Morita, S., Kitamura, S. and Ohta, S.: Effect of tea beverages on aldehyde oxidase activity. Drug Metab. Pharmacokinet., 26: 94-101 (2011).
32. Rodrigues, A. D.: Comparison of levels of aldehyde oxidase with cytochrome P450 activities in human liver in vitro. Biochem. Pharmacol., 48: 197-200 (1994).
33. Sugihara, K., Kitamura, S., Tatsumi, K., Asahara, T. and Dohi, K.: Differences in aldehyde oxidase activity in cytosolic preparations of human and monkey liver. Biochem. Mol. Biol. Int., 41: 1153-1160 (1997).
34. Al-Salmy, H. S.: Individual variation in hepatic aldehyde oxidase activity. IUBMB Life, 51: 249-253 (2001).